| Literature DB >> 27911225 |
Akitake Mukasa1, Shunsuke Yanagisawa1, Kuniaki Saito1, Shota Tanaka1, Keisuke Takai1, Junji Shibahara2, Masachika Ikegami3, Yusuke Nakao3, Katsushi Takeshita3, Masao Matsutani4, Nobuhito Saito1.
Abstract
Primary spinal germ cell tumors are rare, and spinal nongerminomatous germ cell tumors represent an even rarer subset for which no standard therapy has been established. The authors report the case of a 24-year-old woman with multifocal primary spinal germ cell tumors scattered from T-12 to L-5 that consisted of yolk sac tumor and mature teratoma. After diagnostic partial resection, the patient was treated with 30 Gy of craniospinal irradiation and 30 Gy of local spinal irradiation, followed by 8 courses of chemotherapy based on ifosfamide, cisplatin, and etoposide (ICE). Salvage surgery was also performed for residual mature teratoma components after the third course of ICE chemotherapy. Chemotherapy was continued after the operation, but ifosfamide was entirely eliminated from the ICE regimen because severe myelosuppression was observed after previous courses. The patient remains recurrence free as of more than 5 years after the completion of chemotherapy. This case suggests that this treatment strategy is an effective option for primary spinal yolk sac tumor.Entities:
Keywords: AFP = alpha-fetoprotein; BEP = bleomycin, etoposide, and cisplatin; CE = carboplatin and etoposide; CNS = central nervous system; ICE = ifosfamide, cisplatin, and etoposide; JPBTSG = Japanese Pediatric Brain Tumor Study Group; NGGCT = nongerminomatous germ cell tumor; OS = overall survival rate; PE = cisplatin and etoposide; PVB = cisplatin, vinblastine, and bleomycin; STGC = syncytiotrophoblastic giant cell; chemotherapy; germ cell tumor; oncology; radiotherapy; spinal cord; teratoma; yolk sac tumor
Mesh:
Substances:
Year: 2016 PMID: 27911225 DOI: 10.3171/2016.8.SPINE16465
Source DB: PubMed Journal: J Neurosurg Spine ISSN: 1547-5646